Navigation Links
Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
Date:12/4/2008

AMSTERDAM, December 4 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that it has successfully completed treatment of the last patient on its ATIR(TM) phase I/II clinical trial. ATIR(TM), a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a mismatched bone marrow transplantation. Nineteen end stage blood cancer patients were treated with no cases of grade III/IV acute GvHD occurring within the first 100 days after ATIR(TM) infusion, showing the feasibility and tolerability of the addition of ATIR(TM) in combination with a mismatched transplant procedure.

Following scientific advice from the EMEA Kiadis Pharma is preparing to initiate a multi center multinational pivotal study starting recruitment early 2009. In this study the efficacy of ATIR(TM) will be investigated in patients diagnosed with AML, ALL or MDS eligible for an allogeneic bone marrow transplantation but for whom no matching donor is available.

"Bone marrow transplantations are often the only treatment option left for end-stage blood cancer patients. But too many patients simply do not find a suitable matched donor in time" says Dr. Denis-Claude Roy of the Maisonneuve-Rosemont Hospital in Montreal, the principal investigator on the study. "Our study shows a rapid immune reconstitution in transplanted patients provided with ATIR(TM) treated immune cells from mismatched donors. Without ATIR(TM) treatment this would not be possible because of the high risk of acute Graft versus Host Disease with mismatched donor immune cells. This is obviously a very hopeful development for a large patient group."

Dr. Manja Bouman, CEO of Kiadis Pharma, says "The results of this clinical trial are very encouraging and it is another important milestone in the development of ATIR(TM) as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients."

For the complete press release please go to: http://www.kiadis.com/news

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.


'/>"/>
SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
2. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
5. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
6. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
7. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
8. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
9. Isogen Launches Major New Facility to Address Global Biopharma Demand
10. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
11. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... it has earned a spot on Forbes, ... was ranked among 500 U.S. employers as well as ... and Services. The annual Forbes ... survey of over 30,000 employees across 25 industries. The ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... gather at Boston CEO 2017 on May 30th and 31st at The Four ... forum for leading executives in the life sciences, offering exclusive access to key ...
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
(Date:5/26/2017)... ... , ... A new analysis of community health data reveals that four out ... Midwest. With the average cost of healthcare rising and the U.S. senior population expected ... and affordability of where they live. An annual 2017 report looked at a variety ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. ... “We are thrilled to partner with Cupron® to provide customers with a game ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... After raising ... Antzy Top gadget will continue to be available at a discounted crowdfunding price on ... with stress wherever they are, I also wanted to bring a fidget toy to ...
Breaking Medicine News(10 mins):